With this clearance, the respiratory pathogen panel is ready to enter the market to aid in accurate patient diagnosis for respiratory illness.
The firm is selling stock and warrants to purchase stock to raise money for general corporate purposes and working capital.
The molecular diagnostics company posted record revenues to meet Wall Street's estimate but feel short of estimates on the bottom line.
The Austin, Texas-based molecular diagnostics firm logged $60.6 million in Q3 revenues as its system sales shot up 26 percent to $9.6 million.
Bio-Techne is the second firm to sign an instrument distribution deal with Luminex in recent weeks and will continue to develop assays for the Luminex platform.
The panel is designed to simultaneously detect 21 respiratory pathogens including several atypical bacteria in a single closed-tube system.
As part of the deal, Affymetrix will sell Luminex's Magpix, Luminex 200, and Flexmap 3D multiplexed assay platforms in specified geographies.
The firm plans to officially launch and introduce the PCR-based platform and herpes assay over the next several weeks.
Previously for research use only, the Respiratory Pathogen Test for the Verigene System is Nanosphere's fifth infectious disease test to receive FDA clearance.
The Northbrook, Illinois-based molecular diagnostics firm said that sales for its blood culture tests in the quarter increased 87 percent year over year.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.